Zacks Investment Research cut shares of Koninklijke DSM (NASDAQ:RDSMY) from a buy rating to a hold rating in a report published on Tuesday morning.

According to Zacks, “DSM N V ADR is involved in the Chemicals Industry. Their main focus is on base materials, performance materials, materials processing, base chemicals and fine chemicals and coating resins. They are also involved in the exploration and development of oil and natural gas deposits in the North Sea, as well as the licensing of chemical technology and know-how; in addition the company produces ingredients for bakery products. DSM is a world market leader in a number of products, including caprolactam, melamine and EPDM synthetic rubber. “

Separately, HSBC Holdings plc started coverage on shares of Koninklijke DSM in a research note on Friday, September 1st. They issued a buy rating on the stock.

Koninklijke DSM (NASDAQ:RDSMY) opened at 20.23 on Tuesday. Koninklijke DSM has a 12 month low of $14.50 and a 12 month high of $20.30. The company has a market capitalization of $14.15 billion and a PE ratio of 16.77. The stock’s 50 day moving average is $19.17 and its 200-day moving average is $18.23.

COPYRIGHT VIOLATION NOTICE: This story was first published by Daily Political and is owned by of Daily Political. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at

Koninklijke DSM Company Profile

Koninklijke DSM N.V. (Royal DSM) is a global science-based company, engaged in offering health, nutrition and materials. The Company’s segments include Nutrition, Performance Materials, Innovation Center and Corporate Activities. Its Nutrition segment includes DSM Nutritional Products and DSM Food Specialties.

Get a free copy of the Zacks research report on Koninklijke DSM (RDSMY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Koninklijke DSM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM and related companies with's FREE daily email newsletter.